These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression. Poretti MB; Sawant RS; Rask-Andersen M; de Cuneo MF; Schiöth HB; Perez MF; Carlini VP Psychopharmacology (Berl); 2016 Mar; 233(6):1077-86. PubMed ID: 26700241 [TBL] [Abstract][Full Text] [Related]
3. Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors. Schmidt ED; Aguilera G; Binnekade R; Tilders FJ Neuroscience; 2003; 116(1):275-83. PubMed ID: 12535959 [TBL] [Abstract][Full Text] [Related]
4. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Griebel G; Holsboer F Nat Rev Drug Discov; 2012 May; 11(6):462-78. PubMed ID: 22596253 [TBL] [Abstract][Full Text] [Related]
5. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Holmes A; Heilig M; Rupniak NM; Steckler T; Griebel G Trends Pharmacol Sci; 2003 Nov; 24(11):580-8. PubMed ID: 14607081 [TBL] [Abstract][Full Text] [Related]
6. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Grigoriadis DE Expert Opin Ther Targets; 2005 Aug; 9(4):651-84. PubMed ID: 16083336 [TBL] [Abstract][Full Text] [Related]
10. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Nielsen DM Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764 [TBL] [Abstract][Full Text] [Related]
12. The neurobiology of depression: inroads to treatment and new drug discovery. Nemeroff CB; Vale WW J Clin Psychiatry; 2005; 66 Suppl 7():5-13. PubMed ID: 16124836 [TBL] [Abstract][Full Text] [Related]
13. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. Valdez GR CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726 [TBL] [Abstract][Full Text] [Related]
14. Chronic activation of NPFFR2 stimulates the stress-related depressive behaviors through HPA axis modulation. Lin YT; Liu TY; Yang CY; Yu YL; Chen TC; Day YJ; Chang CC; Huang GJ; Chen JC Psychoneuroendocrinology; 2016 Sep; 71():73-85. PubMed ID: 27243477 [TBL] [Abstract][Full Text] [Related]
15. Ghrelin effects expression of several genes associated with depression-like behavior. Poretti MB; Rask-Andersen M; Kumar P; Rubiales de Barioglio S; Fiol de Cuneo M; Schiöth HB; Carlini VP Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():227-34. PubMed ID: 25286107 [TBL] [Abstract][Full Text] [Related]
16. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428 [TBL] [Abstract][Full Text] [Related]
17. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. Stout SC; Owens MJ; Nemeroff CB J Pharmacol Exp Ther; 2002 Mar; 300(3):1085-92. PubMed ID: 11861819 [TBL] [Abstract][Full Text] [Related]
19. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Wigger A; Sánchez MM; Mathys KC; Ebner K; Frank E; Liu D; Kresse A; Neumann ID; Holsboer F; Plotsky PM; Landgraf R Neuropsychopharmacology; 2004 Jan; 29(1):1-14. PubMed ID: 12942143 [TBL] [Abstract][Full Text] [Related]
20. CRF receptors as a potential target in the development of novel pharmacotherapies for depression. Valdez GR Curr Pharm Des; 2009; 15(14):1587-94. PubMed ID: 19442175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]